Free Trial
NASDAQ:ASMB

Assembly Biosciences Q3 2026 Earnings Results & Report

Assembly Biosciences logo
$20.18 -2.19 (-9.79%)
Closing price 04:00 PM Eastern
Extended Trading
$20.87 +0.69 (+3.44%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Assembly Biosciences missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.93 versus the -$0.6550 consensus estimate, while revenue of $2.96 million fell short of the $9.07 million estimate by $6.12 million.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
4:00 PM ET

Assembly Biosciences EPS Results

Actual EPS
-$0.93
Consensus EPS
-$0.6550
Beat/Miss
Missed by -$0.2750
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Assembly Biosciences Revenue Results

Actual Revenue
$2.96 million
Expected Revenue
$9.07 million
Beat/Miss
Missed by -$6.12 million
YoY Revenue Growth
N/A

Assembly Biosciences Q3 2026 Earnings FAQ

Assembly Biosciences (NASDAQ:ASMB) reported earnings of -$0.93 per share for Q3 2026, missing the consensus estimate of -$0.6550. The report was announced on Thursday, November 12, 2026.

Assembly Biosciences reported revenue of $2.96 million for Q3 2026, against a consensus estimate of $9.07 million.

Assembly Biosciences Earnings Headlines

Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.tc pixel
See More Assembly Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Assembly Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Assembly Biosciences and other key companies, straight to your email.

About Assembly Biosciences

Assembly Biosciences (NASDAQ:ASMB) is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus.

The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.

Based in South San Francisco, California, Assembly Biosciences conducts drug research and development with the goal of addressing significant unmet needs in viral disease treatment.

View Assembly Biosciences Profile